Chardan Capital Reaffirms Buy Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a report issued on Wednesday,Benzinga reports. They currently have a $24.00 price target on the stock. Chardan Capital’s target price indicates a potential upside of 188.12% from the stock’s current price.

STOK has been the topic of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. Finally, HC Wainwright boosted their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $8.33 on Wednesday. The company’s 50 day simple moving average is $9.49 and its 200 day simple moving average is $11.49. Stoke Therapeutics has a 12 month low of $5.80 and a 12 month high of $17.58. The company has a market capitalization of $441.22 million, a P/E ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. On average, analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock worth $143,332 in the last ninety days. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $63,000. Teacher Retirement System of Texas acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $124,000. Tower Research Capital LLC TRC increased its position in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $133,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.